Swiss All Share Index

Swiss All Share Index handeln
18.222,33 PKT +57,51 PKT +0,32 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

ISIN CH0009111011


Analysen zu Swiss All Share Index-Werten

Datum Rating Analyst
31.01.05 Lonza Reduce Sarasin Research
31.01.05 Novartis Outperform Credit Suisse First Boston
01.02.05 Roche Neutral Credit Suisse First Boston
02.02.05 UBS Outperform Credit Suisse First Boston
31.01.05 Vetropack A Market Perform Vontobel
01.02.05 ARYZTA Buy Helvea
31.01.05 Roche Buy Sarasin Research
01.02.05 Logitech Kauf SYZ & CO
01.02.05 Schindler Neutral Helvea
31.01.05 Nestlé Neutral Sarasin Research
31.01.05 Novartis Buy Helvea
31.01.05 Swatch (I) Buy Sarasin Research
28.01.05 Holcim Verkaufen Helaba Trust
27.01.05 Lonza Buy Helvea
03.02.05 Novartis Outperformer Sparkasse KölnBonn
28.01.05 Swatch (I) Neutral JP Morgan
27.01.05 Holcim Neutral Helvea
27.01.05 Adecco SA Accumulate Helvea
27.01.05 Holcim Halten Helaba Trust
26.01.05 Novartis Market Perform William Blair
26.01.05 UBS Buy Sarasin Research
26.01.05 Lonza Reduce Sarasin Research
26.01.05 Lindt In-Line Goldman Sachs
26.01.05 ARYZTA Neutral Sarasin Research
26.01.05 Lindt Neutral Sarasin Research
25.01.05 Adecco SA Accumulate Helvea
25.01.05 Holcim Accumulate Helvea
25.01.05 Novartis Buy Helvea
25.01.05 Lindt Neutral Helvea
25.01.05 Swisscom Underweight Lehman Brothers
25.01.05 Novartis Halten LB Baden-Württemberg
26.01.05 Nestlé Outperform Credit Suisse First Boston
25.01.05 Novartis Outperform Goldman Sachs
25.01.05 Lonza Overweight JP Morgan
25.01.05 UBS Buy Helvea
24.01.05 Novartis Overweight Prudential Securities
24.01.05 Holcim Neutral Sarasin Research
25.01.05 Novartis Neutral Sarasin Research
24.01.05 Richemont Outperform Goldman Sachs
24.01.05 Novartis Neutral Sarasin Research